
A2B receptor antagonist 2
CAS No. 784-90-7
A2B receptor antagonist 2( —— )
Catalog No. M28147 CAS No. 784-90-7
A2B receptor antagonist 2 is an antagonist of adenosine receptor A2B (Ki = 2.30 μM for rA1, 6.8 μM for rA2A, 3.44 μM for hA2B).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
25MG | 57 | Get Quote |
![]() ![]() |
50MG | 83 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameA2B receptor antagonist 2
-
NoteResearch use only, not for human use.
-
Brief DescriptionA2B receptor antagonist 2 is an antagonist of adenosine receptor A2B (Ki = 2.30 μM for rA1, 6.8 μM for rA2A, 3.44 μM for hA2B).
-
DescriptionA2B receptor antagonist 2 is an antagonist of adenosine receptor A2B (Ki = 2.30 μM for rA1, 6.8 μM for rA2A, 3.44 μM for hA2B).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetAdenosine Receptor
-
RecptorCD11b
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number784-90-7
-
Formula Weight229.287
-
Molecular FormulaC12H15N5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 2 mg/mL (8.72 mM)
-
SMILESCc1cc2nc(NC(N)=N)nc(C)c2cc1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Panni RZ, et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci Transl Med. 2019 Jul 3;11(499).
molnova catalog



related products
-
ZM-241385
ZM-241385 is a potent, non-xanthine A2A selective adenosine receptor antagonist with rat PC12 binding pIC50 of 9.52.
-
Metipranolol
Metipranolol is a β-adrenergic receptor antagonist that is given orally for the treatment of hypertension and also applied topically to the cornea for treating glaucoma.
-
eN-IN-1
An α,β-Methylene-ADP (AOPCP) derivative, potent, selective ecto-5′-Nucleotidase (eN, CD73) inhibitor with Ki of 29 nM for rat recombinant eN.